TENAX THERAPEUTICS, INC.
TENAX THERAPEUTICS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 30, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 38 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 5 concluded trials, 60% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 30, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 30, 2028 | LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | Trial Milestone | Phase 3 |
| March 15, 2029 | Long-Term Open-Label Extension Study of Oral Levosimendan | Trial Milestone | Phase 3 |
Track TENX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open TENX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.